M&A Deal Summary

AnGes Acquires EmendoBio

On December 15, 2020, AnGes acquired life science company EmendoBio for 250M USD

Acquisition Highlights
  • This is AnGes’ 1st transaction in the Life Science sector.
  • This is AnGes’ largest (disclosed) transaction.
  • This is AnGes’ 1st transaction in the United States.
  • This is AnGes’ 1st transaction in New York.

M&A Deal Summary
Date 2020-12-15
Target EmendoBio
Sector Life Science
Buyer(s) AnGes
Deal Type Add-on Acquisition
Deal Value 250M USD
Advisor(s) Morgan Lewis (Legal)

Target

EmendoBio

New York, New York, United States
EmendoBio, Inc. is a CRISPR gene-editing company leveraging dual proprietary technology platforms to enable high precision gene-editing throughout the genome. EmendoBio’s novel nuclease discovery platform broadens the targetable range of the genome while its target‐specific optimization platform enables highly precise editing, including allele-specific editing while maintaining high efficiencies. EmendoBio is based in New York City.

Search 198,242 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

AnGes

Ibaraki, Japan
Category Company
Founded 1999
Sector Life Science
Employees145
Revenue 153M JPY (2023)
DESCRIPTION

AnGes is a biopharmaceutical company focuses on the development of gene?based medicines. AnGes obtained conditional and time?limited approval for its lead product, Collategene (Hepatocyte Growth Factor, HGF, plasmid gene therapy), for the treatment of Lower Limb Ischemic Ulcers. In September 2019, AnGes commenced the commercialization in Japan of Collategene . Collategene is the world’s first marketed drug-using Plasmid DNA. AnGes is currently focusing on the development of DNA vaccines for COVID?19 and Hypertension, Tie2 tyrosine kinase receptor agonist for COVID?19 treatment, and NF??B decoy oligonucleotide for Chronic Discogenic Lumbar Back Pain. AnGes was founded in 1999 and is based in Ibaraki, Japan.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (New York) 1 of 1
Country (United States) 1 of 1
Year (2020) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal